Company profile for Newron Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights...
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
89 Headquarters Plaza North - Suite 306 Morristown, NJ 07960
Telephone
Telephone
+1 973 993 1873
Client Website
Website
--
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251002836097/en/Newron-to-Present-New-Analyses-From-and-Updates-on-its-Clinical-Program-Evaluating-Evenamide-as-an-Add-on-Treatment-for-Schizophrenia-at-the-38th-European-College-of-Neuropsychopharmacology-ECNP-Congress-2025

BUSINESSWIRE
02 Oct 2025

https://www.pharmiweb.com/press-release/2025-09-16/newron-presents-h1-2025-results-and-provides-business-update

PHARMAWEB
16 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-05/newron-to-present-data-and-updates-on-its-clinical-program-evaluating-evenamide-as-an-add-on-treatme

PHARMAWEB
05 Sep 2025

https://www.businesswire.com/news/home/20250812127452/en/Newron-Begins-Enrollment-in-Pivotal-Phase-III-ENIGMA-TRS-Program-With-Evenamide-as-Add-on-Therapy-in-Patients-With-Treatment-Resistant-Schizophrenia-TRS

BUSINESSWIRE
12 Aug 2025

https://www.businesswire.com/news/home/20250811493586/en/Newron-Notes-the-Publication-of-New-Preclinical-Research-Suggesting-Evenamide-Ameliorates-Schizophrenia-Related-Dysfunction

BUSINESSWIRE
11 Aug 2025

https://www.pharmiweb.com/press-release/2025-08-11/newron-notes-the-publication-of-new-preclinical-research-suggesting-evenamide-ameliorates-schizophre

PHARMAWEB
11 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty